[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Parma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":215},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,80,110,131,161,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100643567","personalizing-preterm-neonatal-transfusions-with-fetal-hemoglobin-enriched-cord-blood-100643567",false,"NCT07636473","Personalizing Preterm Neonatal Transfusions With Fetal Hemoglobin-Enriched Cord Blood","Advancing Neonatal Health: Personalizing Preterm Neonatal Transfusions With Fetal Hemoglobin-Enriched Cord Blood","ANH-Prestige","Inclusion Criteria:\n\n* Preterm neonates born between 24+0 and 31+6 weeks of gestational age;\n* Requirement for at least one red blood cell transfusion during hospitalization, according to current Italian transfusion thresholds;\n* Written informed consent obtained from parents or legal guardians prior to any study procedure.\n\nExclusion Criteria:\n\n* Gestational age \\> 32+0 weeks;\n* Pregnancy complicated by maternal-fetal alloimmunization (e.g., hemolytic disease of the newborn);\n* Pregnancy complicated by fetal hydrops;\n* Major congenital anomalies or genetic syndromes;\n* Previous red blood cell transfusions (prior to enrollment);\n* Perinatal hemorrhage at delivery;\n* Documented congenital infections (TORCH).","ALL","24 Weeks","31 Weeks",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","Long-term morbidities among very low birth weight infants remain a significant challenge. Oxidative stress is a key factor in the pathogenesis of 'free radical (FR) diseases of prematurity,' including retinopathy of prematurity, bronchopulmonary dysplasia, necrotizing enterocolitis, and intraventricular hemorrhage. Red blood cell (RBC) transfusions are recognized as a contributing factor to FR-related diseases. RBCs contain adult hemoglobin (HbA), which has a lower affinity for oxygen. This characteristic increases oxygen delivery and tissue uptake, leading to a potentially harmful state of hyperoxia and over-generation of FRs. The strategy employs a multidisciplinary approach to evaluate the impact of cord blood transfusions in anemic newborns. Results will be assessed in relation to short- and long-term neonatal outcomes to determine the effectiveness of this new preventive strategy. Improving the current data are critical for setting action priorities for and monitoring progress",[28,29],"Prematurity Complications","Anemia",[31,32,33],"Cord Blood red blood cells","transfusion","preterm newborns","NOT_YET_RECRUITING","2026-06-09",{"date":37,"type":38},"2026-06-11","ACTUAL",{"date":40,"type":22},"2026-11-01",{"date":42,"type":22},"2029-11-01",{"name":44,"class":45},"University of Parma","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100600619","hyaluronic-acid-and-polynucleotides-in-ridge-preservation-100600619","NCT07099846","Hyaluronic Acid and Polynucleotides in Ridge Preservation","The Use of Hyaluronic Acid and Polynucleotides in Ridge Preservation Sites Rehabilitated With a Complete Full Digital Workflow","P-005","Inclusion Criteria:\n\n* ≥25-year-old males and females;\n* good systemic health (self-assessment);\n* presence of an unrestorable\u002Fhopeless tooth with periodontal attachment and buccal bone preserved at least for 2\u002F3rd of the root and not associated with acute periapical pathology;\n* full mouth bleeding and plaque scores ≤ 25%\n\nExclusion Criteria:\n\n* uncontrolled or untreated periodontal disease;\n* history of local (head and neck) radiation therapy in the past 5 years;\n* acute endodontic lesion in the test tooth or in the neighbouring areas to the extraction procedure (sites with presence of an asymptomatic chronic lesion are eligible);\n* medical history that includes uncontrolled diabetes or hepatic or renal disease, or other serious medical conditions that can impact on bone metabolism (e.g. rheumatoid arthritis, osteoporosis) or transmittable diseases (e.g. HIV-related disease);\n* history of alcohol or drug abuse;\n* smokers of ≥10 cigarettes a day;\n* self-reported pregnancy or lactation.","25 Years",{"count":56,"type":22},40,[25],"The aim of this study is to test the use of a bovine-derived bone graft combined with a polynucleotides-rich hyaluronic acid (PNHA) gel for the preservation of the bone after a tooth extraction (alveolar ridge preservation) and to test the performance of a fully-digital workflow to rehabilitate the site with a dental implant. 40 patients in need for a single tooth extraction will be recruited at Centro di Odontoiatria, Università di Parma and they will be randomly assigned to 2 groups: extraction and spontaneous healing or extraction and regeneration of the site with a bovine-derived bone graft combined with a PNHA gel. At 4 months after extraction an implant will be placed in the extraction site, which will be rehabilitated with a fully-digital workflow and patients will be followed up at up to 12 months post rehabilitation. Two 3D x-rays with a small field of view will be performed immediately after extraction and at 4 months post extraction to plan implant placement. These images will also be used to assess changes in the dimension of the post extraction bone (primary outcome). As part of the study different questionnaires will be administered to assess quality of life and perception of the therapy and the wound exudate in the area of the extraction will be collected non invasively with a collagen sponge to assess the expression of different proteins during the early healing days. On the day of implant placement a sample of bone tissue will also be collected as part of the bone drilling and histologically analysed.",[60,61,62,63],"Socket Preservation","Implant-supported Single Crowns","Hyaluronic Acid","CAD-CAM",[65,66,67,68,63,69],"alveolar ridge preservation","hyaluronic acid","polynucleotides","digital workflow","Implant rehabilitation","RECRUITING","2025-09-01",{"date":73,"type":38},"2025-09-08",{"date":75,"type":38},"2025-06-09",{"date":77,"type":22},"2028-05",{"name":44,"class":45},2,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100588684","impact-of-sleep-disorders-and-digital-support-on-older-peoples-health-100588684","NCT06944600","Impact of Sleep Disorders and Digital Support on Older People's Health","The Role of Sleep Disorders in the Motoric and Cognitive Trajectories of Older Physically Frail Sarcopenic and Healthy Active Subjects","SOMNUS-DARE","Inclusion Criteria:\n\n* Age ≥ 65 years;\n* MMSE score adjusted by age and education ≥ 25\u002F30;\n* Absence of mobility-disability;\n* Absence of need for assistance with Basic Activities of Daily Living (according to the ICFSR International Clinical Practice Guidelines).\n\nExclusion Criteria:\n\n* Individuals with specific clinical conditions that make the intervention unsafe (I.e., severe diseases, unstable health status);\n* Individuals whose adherence to the protocol might be low due to clinical (E.g., cognitive impairment, dialysis) and non-clinical (E.g., plans to relocate out of the study area within the next 3 years) reasons;\n* Individuals unable or unwilling to provide informed consent;\n* Consumption of more than 14 alcoholic drinks per week \\[one alcoholic drink (equal to 14.0 grams of pure alcohol) corresponds to 36 cc of beer (5% alcohol content), 24 cc of malt liquor (7% alcohol content), 15 cc of wine (12% alcohol content), 4.5 cc of distilled spirit or liquor (40% alcohol content)\\];\n* Difficulty in communicating with the study staff due to speech, language, or (non-corrected) hearing and vision problems;\n* Severe arthritis (E.g., awaiting joint replacement) that would interfere with the ability to fully participate in the study;\n* Lung disease requiring regular use of supplemental oxygen;\n* Severe cardiovascular disease (including New York Heart Association \\[NYHA\\] class III or IV, clinically significant congestive heart failure and valvular disease, history of cardiac arrest, presence of an implantable defibrillator or pacemaker, uncontrolled angina);\n* Upper and\u002For lower extremity amputation;\n* Peripheral arterial disease Lériche-Fontaine 3 or 4;\n* Renal disease requiring dialysis;\n* Current enrolment in another study involving lifestyle, nutrition, or pharmaceutical interventions;\n* Further medical, psychiatric, or behavioural factors that in the judgment of the principal investigator may interfere with the study participation;\n* Further possible illnesses affecting the life expectancy and reducing it to less than 24 months, corresponding to the study's length;\n* Clinical judgment concerning safety or non-compliance, as well as the conditions for which the use of the Sleep Profiler is not recommended (sensitivity of skin or scalp and\u002For open wounds on the forehead or scalp, allergic reactions to extended exposure to synthetic fabrics (e.g., polyester, rayon), upper respiratory infection or congestion, head circumference less than 21 or greater than 25 inches, forehead vertical measurement (from top of eyebrows to hairline) less than or equal to 2 inches or horizontal measurement (from hairline to hairline) less than or equal to 6 inches).\n* SPPB score \\\u003C3 at baseline.",true,"65 Years",{"count":91,"type":22},300,"OBSERVATIONAL","The goal of this observational study is to learn about the effects of sleep disorders on health and ageing in older people over the age of 65.\n\nThe main question it aims to answer is: How do sleep disorders impact the motoric and cognitive ageing trajectories of older individuals? Participants will undergo a set of instrumental, laboratory and clinical diagnostic examinations to comprehensively assess the impact of sleep disorders on health.",[95,96,97,98,99,100,101],"Sleep Disorders","Frailty","Cognitive Impairment","Quality of Life","Ageing","Digital Health","Multidisciplinary Approach","2025-04-17",{"date":104,"type":38},"2025-04-25",{"date":106,"type":22},"2025-05",{"date":108,"type":22},"2027-11",{"name":44,"class":45},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100446077","comparing-different-timings-for-periodontal-re-evaluation-after-non-surgical-periodontal-therapy-nspt-100446077","NCT05088746","Comparing Different Timings for Periodontal Re-evaluation After Non-surgical Periodontal Therapy (NSPT)","Inclusion Criteria:\n\n* Systemically healthy males and females ≥18 years old\n* Willingness to read and sign a copy of the Informed Consent Form after reading the Patient Information Sheet, and after the nature of the study has been fully explained\n* Clinical evidence of periodontitis, defined as the presence of interdental clinical attachment loss detectable at ≥2 non-adjacent teeth or buccal or oral clinical attachment loss ≥3mm with pocketing \\>3 mm detectable at ≥2 teeth (Tonetti et al., 2018)\n* Not having received subgingival instrumentation within the previous 12 months\n\nExclusion Criteria:\n\n* Medical history that includes serious medical conditions or transmittable diseases (e.g. serious cardiovascular disease, organ transplant, renal failure, AIDS, viral etc.).\n* Antibiotic, anti-inflammatory or anticoagulant therapy during the month preceding the baseline exam.\n* In treatment with drugs that induce gingival overgrowth\n* History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures\n* History of alcohol or drug abuse.\n* Self-reported pregnancy or lactation (this criterion is due to oral tissue changes related to pregnancy and nursing, which can affect interpretation of study results).\n* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgement of the investigator, would make the subject inappropriate for entry into this trial.","18 Years",{"count":118,"type":22},52,"This is a prospective cohort study that aims to describe the difference in terms of percentage of closed pockets (PPD \\\u003C5 mm and no BOP) when performing the periodontal re-evaluation at 3-4, 6-8 and 12 months.\n\nFifty-two, ≥18-year old, otherwise healthy, periodontitis patients will be recruited at Centro di Odontoiatria, Università di Parma.",[121,122],"Periodontitis","Periodontal Pocket","2025-04-16",{"date":102,"type":38},{"date":126,"type":38},"2021-06-01",{"date":128,"type":22},"2026-12-31",{"name":44,"class":45},1,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":88,"sex":17,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":142,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":130},"100518293","investigation-of-in-vivo-endogenous-andor-exogenous-production-of-phenolic-metabolites-using-untargeted-metabolomics-100518293","NCT06028659","Investigation of in Vivo Endogenous and\u002For Exogenous Production of Phenolic Metabolites Using (un)Targeted Metabolomics","ENDOPHENOL","Inclusion Criteria:\n\n* Apparently healthy adults,\n* Age 20-40 years old,\n* Body mass index (BMI) between 18-28,\n* Regular coffee consumers (at least 1 cup a day).\n\nExclusion Criteria:\n\n* Clinical diagnosis of metabolic diseases,\n* Clinical diagnosis of cardiovascular diseases,\n* Clinical diagnosis of renal diseases,\n* Clinical diagnosis of digestive diseases,\n* Immunodeficiency\n* Autoimmune diseases (other than well-compensated hypothyroidism),\n* Mental disorders\n* Regular use of medication (except birth-control pills and hormone replacement therapies),\n* Use of antibiotics in the last month prior to enrollment,\n* Food allergies or intolerances,\n* Pregnancy\n* Lactation","20 Years","40 Years",{"count":141,"type":22},30,[25],"Plant (poly)phenols is what we call a large number of substances that are produced by plants as secondary plant metabolites, which means substances that are not used for their growth and development but are necessary for them to survive. (Poly)phenols are divided in two major groups, flavonoids, and non-flavonoids, and each group contains a varied set of subgroups and substances. They are widely spread in fruit and vegetables that are part of the human diet, and, in general, studies have attributed many biological effects to the ingestion of (poly)phenols, especially in the prevention of non-communicable diseases. For this reason, research aims to understand their role in the health benefits of a diet that is rich in fruits and vegetables. When ingested, (poly)phenols are digested by both the human organism and the gut microbiota and are broken down into several smaller substances (catabolites) that are called low-molecular weight (poly)phenols (LMWP). Most of the absorbed (poly)phenols that reach our bloodstream and organs are LMWP.\n\nFor the proposed study, 30 healthy adults will be recruited and, if considered able to participate, will follow a standardized diet that is restricted in (poly)phenol intake and will be randomly divided into two groups: one will receive a known source of (poly)phenols (coffee) and the other will receive water, keeping the restriction of (poly)phenol from the diet. The duration of one phase is 4 days + 12 hours, during which urine, feces, and saliva will be collected. Then, after a 2-week-interval, subjects will repeat the experiment, except that this time the group who had coffee will have water, and vice versa. Again, urine and feces will be collected. The objective of the study is to identify and quantify LMWP mainly in urine, but also in feces, and try to understand how much was produced when there was no (poly)phenols in the diet compared with when there was ingestion of coffee (poly)phenols. The production of LMWP without coffee could be because of their production from other sources, like the metabolism of amino acids, proteins, and catecholamines (i.e. dopamine). The composition of the gut microbiota and relevant genetic information can alter the metabolism of (poly)phenols and will be considered in the analyses. Knowing how much of LMWP actually comes from the diet is important to understand the relevance and health benefits of these molecules.",[145],"Individual Variability in (Poly)Phenol Metabolism",[147,148,149,150,151,152],"(poly)phenols","catabolites","coffee","metabolism","low-molecular-weight (poly)phenols","metabolomics","2025-04-03",{"date":155,"type":38},"2025-04-08",{"date":157,"type":38},"2023-10-25",{"date":159,"type":22},"2025-06-30",{"name":44,"class":45},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":172,"conditions":173,"keywords":176,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":130},"100573281","olfactory-testing-in-perinatal-asphyxia-enhancing-risk-assessment-100573281","NCT06744244","Olfactory Testing in Perinatal Asphyxia: Enhancing Risk Assessment","Olfactory Memory in Infants With Signs of Asphyxia: An Early Indicator of Neurodevelopmental Outcomes","MEMOBRAIN","Inclusion Criteria:\n\n* Term newborns (37-41 weeks of gestational age) with signs of asphyxia at birth (cord pH \\\u003C 7.10 and\u002For BE \\> -12).\n* Maternal age \\> 18 years.\n* No medication use during pregnancy (e.g., antipsychotics, antidepressants, sedatives, anticonvulsants, anxiolytics).\n* Absence of maternal infections.\n* Apgar score \\\u003C 5 at 10 minutes of life.\n* Newborns with mild asphyxia at birth.\n* Newborns with moderate asphyxia at birth, at risk of developing hypoxic-ischemic encephalopathy, who don't need hypothermia treatment.\n* Newborns with severe asphyxia at birth, at risk of developing hypoxic-ischemic encephalopathy who don't need hypothermia treatment.\n\nExclusion Criteria:\n\n* Post-term infants (gestational age \\> 42 weeks).\n* Preterm infants (gestational age \\\u003C 37 weeks).\n* Infants with genetic syndromes or congenital anomalies.\n* Infants from mothers using drugs of abuse.\n* Infants with scalp injuries or lesions.\n* Infants with microcephaly.\n* Infants who underwent therapeutic hypothermia.","6 Hours","72 Hours",{"count":141,"type":22},"Neonatal asphyxia remains a leading cause of neurodevelopmental disabilities despite advancements in perinatal care. Hypoxic-ischemic encephalopathy (HIE), a severe outcome of asphyxia, impacts 1-3 infants per 1,000 live births annually in industrialized nations, causing long-term neurological impairments such as cognitive dysfunction, motor deficits, and sensory impairments. Early identification of at-risk newborns is critical to initiate timely interventions and improve outcomes.\n\nOlfactory perception, crucial for newborns' adaptation to extrauterine life, involves odor identification and memory. Odor perception is known to be impaired in adults with neurological disorders and in animal models of brain injury. However, no clinical studies have assessed olfactory function in newborns with signs of asphyxia. Olfactory memory, which can be evaluated through habituation to repeated odors, may provide insights into early brain function.\n\nThis study aims to evaluate whether olfactory memory can serve as an early marker of neurodevelopmental outcomes in newborns with signs of asphyxia. By assessing physiological, behavioral, and neurological responses to olfactory stimuli, the study seeks to explore the differences between infants with mild asphyxia and those with moderate-to-severe asphyxia.",[174,175],"Mild Birth Asphyxia","Moderate Birth Asphyxia",[177,178,179,180],"Perinatal Asphyxia","Hypoxic-Ischemic Encephalopathy","Biomarkers","Olfactory Function","2024-12-30",{"date":183,"type":38},"2024-12-31",{"date":185,"type":38},"2024-09-10",{"date":187,"type":22},"2026-09-10",{"name":44,"class":45},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":199,"conditions":200,"keywords":203,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":130},"100296774","prospective-european-multicenter-study-on-aortic-valve-replacement-e-avr-registry-100296774","NCT03143361","Prospective European Multicenter Study on Aortic Valve Replacement: (E-AVR Registry)","Outcome Comparison of Different Surgical Strategies for the Management of Severe Aortic Valve Stenosis: Study Protocol of a Prospective Multicentre European Registry (E-AVR Registry)","E-AVR","Inclusion criteria\n\n* Age \\>18 yy\n* Isolated SAVS with or without concomitant aortic valve regurgitation\n* Isolated prosthetic aortic dysfunction\n* SAVS + coronary artery disease (CAD)\n* Prosthetic aortic dysfunction + CAD\n* Elective, urgent and emergent procedures\n* Endocarditic aetiology\n\nExclusion criteria\n\n* Patients undergoing concomitant mitral valve surgery, or tricuspid valve surgery, or aortic surgery (i.e. composite aortic valve and ascending aorta replacement with or without circulatory arrest), or atrial fibrillation surgery, or any other associated cardiac surgical procedure (with the exception of CABG)\n* Concomitant aortic root procedure (i.e. Bentall operation, David operation, homografts, autografts)\n* SAVR with techniques of aortic annular enlargement\n* Porcelain aorta\n* Pure aortic valve regurgitation\n* Percutaneous TAVR requiring surgical cut-down (i.e. failure to comply with a full percutaneous approach, thus configuring a \"hybrid procedure\")\n* Patient refusal",{"count":198,"type":22},8000,"Traditional and transcatheter surgical treatments of severe aortic valve stenosis (SAVS) are increasing in parallel with the improved life-expectancy. Recent randomized trials (RCTs) reported comparable or non-inferior mortality with transcatheter treatments compared to traditional surgery. However, RCTs have the limitation of being a mirror of the predefined inclusion\u002Fexclusion criteria, without reflecting the \"real clinical world\".\n\nTechnological improvements have recently allowed the development of minimally invasive surgical accesses and the use of sutureless valves, but their impact on the clinical scenario is difficult to assess because of the monocentric design of published studies and limited sample-size. A prospective multicentre registry including all patients referred for a surgical treatment of SAVS (traditional, through full-sternotomy; minimally-invasive; or transcatheter; with both \"sutured\" and \"sutureless\" valves) will provide a \"real-world\" picture of available results of current surgical options, and will help to clarify the \"grey zones\" of current guidelines.\n\nE-AVR is a prospective observational open registry designed to collect all data from patients admitted for SAVS, with or without coronary artery disease, in 16 cardiac surgery Centres located in six countries (France, Germany, Italy, Spain, Switzerland, and United Kingdom). Patients will be enrolled over a 2-year period and followed-up for a minimum of 5 years to a maximum of 10 years after enrolment. Outcome definitions are concordant with VARC-2 criteria and established guidelines. Primary outcome is 5-year all-cause mortality. Secondary outcomes aim at establishing \"early\" 30-day all-cause and cardiovascular mortality, as well as major morbidity, and \"late\" cardio-vascular mortality, major morbidity, structural and non-structural valve complications, quality of life and echocardiographic results.\n\nThe study protocol is approved by Local Ethics Committees. Any formal presentation or publication of data will be considered as a joint publication by the participating physician(s) and will follow the recommendations of the International Committee of Medical Journal Editors (ICMJE) for authorship.",[201,202],"Aortic Valve Stenosis","Valve Heart Stenosis",[204,205,206],"aortic valve stenosis","heart valves","heart surgery","2020-03-31",{"date":209,"type":38},"2020-04-03",{"date":211,"type":38},"2017-11-01",{"date":213,"type":22},"2029-10",{"name":44,"class":45},""]